Molecular diagnostic development for children with leukaemia

2018. May 14.
The 25-year-old Béres Foundation held a charity concert. “Life’s what is worth fighting for!” cited Klára Béres, President of Béres Foundation celebrating its 25th anniversary, the words of dr. József Béres Sr. while opening a charity concert for the recovery of children with leukaemia held at the Liszt Ferenc Academy of Music on 10 May. János Balázs pianist, Andrea Vigh harpist and the Dohnányi Orchestra Budafok, conducted by Gábor Hollerung were the main features of the event. The Béres Foundation offered the total incomes of the successful concert to the Hungarian Paediatric Oncology Network. The purpose of the donation is to introduce a new diagnostic method that enables a faster and more customized therapy for children with leukaemia, significantly increasing their chance of recovery.

As Klára Béres said, “We have a good reason to be proud today as the Béres Foundation has been helping the needy and the sick, supporting the education and the culture and serving the creation of value for 25 years. It is a very nice feeling to think about as to how many people and communities we could help and how many we could give recovery, strength and hope in the past quarter-century. This charity event is the eleventh to collect money to help patients with cancer. As always, we were very circumspect in selecting the supported entity. This time our support goes to the introduction of a diagnostic tool that was inaccessible in Hungary until today. It is an up-to-date method on a global scale that gives a significantly increased chance of recovery for seriously ill children.”



On behalf of the Hungarian Paediatric Oncology Network, President Dr. Gergely Kriván thanked for the donation and said, “Functioning since 1971, the Network is an effective cooperation between doctors, caregivers, and other medical professionals who committed their life to heal cancerous children. The newest diagnostic method to be installed with the help of the Béres Foundation is a breakthrough compared to our existing practices and it ensures a so far missing but critical step in the treatment of cancerous children.”



According to dr. Csaba Bödör, Head of the research laboratory of the 1st Department of Pathology and Experimental Cancer Research at Semmelweis University, “The research made it possible to differentiate between several subgroups of paediatric leukaemia where the chance of survival is way less than 50% but the rate of recovery could improve with specified treatment. Thanks to this support, the new diagnostic tool to be introduced in Hungary will provide a groundbreaking method in determining the prognosis and applying targeted therapy that speeds up the process of getting accurate diagnosis and enhances the effectiveness of the patient’s recovery.”


© Copyright 2012 Béres Pharmaceuticals Ltd.

Increst Communication